Fluocinolone Acetonide
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
- Fluocinolone Acetonide
- Fluocinolone Acetonide: From an Undocumented Original Indication to Annular Atrophic Lichen Planus
Fluocinolone Acetonide: From an Undocumented Original Indication to Annular Atrophic Lichen Planus
One-Sentence Summary
Fluocinolone acetonide (DrugBank DB00591) is a high-potency topical corticosteroid; this evidence pack does not contain its original approved indication or mechanism-of-action text, and the product is currently not registered with SAHPRA (0 licenses on file). The TxGNN model predicts possible efficacy for Annular Atrophic Lichen Planus, but this specific prediction is currently supported by the model score alone (99.42%), with no clinical trials and no literature identified for this exact indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack |
| Predicted New Indication | Annular Atrophic Lichen Planus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for fluocinolone acetonide is not available in this evidence pack. Based on the information that is available, fluocinolone acetonide belongs to the class of high-potency topical corticosteroids, which act through anti-inflammatory and immunosuppressive pathways. This class-level mechanism is plausible for inflammatory dermatoses such as lichen planus, which is the biological rationale behind the TxGNN prediction.
However, for the specific predicted indication in this report — annular atrophic lichen planus — no direct or indirect clinical trial or literature evidence was identified in the search performed. The prediction therefore rests entirely on the TxGNN network score, not on any observed clinical or pharmacological data point specific to this variant of lichen planus.
Related predictions in the same disease cluster: This candidate record grouped four closely related lichen planus phenotypes with near-identical TxGNN scores (~99.4%): annular atrophic lichen planus, hypertrophic lichen planus, lichen planus pigmentosus, and lichen planus pemphigoides. Among these, only lichen planus pemphigoides (rank 4, score 99.34%) has supporting literature — three publications describing topical corticosteroids of the same class (fluocinonide, clobetasol propionate, not fluocinolone acetonide itself) used for oral vesiculoerosive/lichen planus-related mucosal disease. This is class-effect evidence, not drug-specific evidence, but it does lend some mechanistic plausibility to the broader lichen planus cluster, including the indication discussed here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for annular atrophic lichen planus.
(For context, three publications support the related indication lichen planus pemphigoides via class-effect evidence — see table below.)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8065723 | 1994 | RCT | Oral Surg Oral Med Oral Pathol | Double-blind trial comparing 0.05% clobetasol propionate vs 0.05% fluocinonide ointment (both potent topical corticosteroids, not fluocinolone acetonide) for oral vesiculoerosive disease |
| 6996618 | 1980 | Cohort/Clinical Trial | Arch Dermatol | Topical fluocinonide in an adhesive base for oral vesiculoerosive diseases including lichen planus and pemphigoid; partial/complete response in a double-blind subgroup |
| 14620208 | 2003 | Review/Case Report | Quintessence Int | Review of desquamative gingivitis as an early presentation of mucocutaneous disease |
South Africa Market Information
This product currently has no SAHPRA registration on file (Market status: Not Marketed, 0 licenses).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: this evidence pack flags the absence of TFDA/SAHPRA label warnings and contraindications as a Blocking data gap (DG001) — safety review cannot proceed to formal assessment until this is resolved.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (annular atrophic lichen planus) is supported only by a TxGNN model score, with no clinical trials or literature identified. The drug also has no current SAHPRA registration and no documented mechanism of action, which prevents any safety or regulatory assessment.
To proceed, the following is needed:
- Mechanism-of-action data for fluocinolone acetonide (flagged as data gap DG002, High severity)
- SAHPRA/TFDA Professional Information, including warnings and contraindications (flagged as data gap DG001, Blocking severity)
- Indication-specific clinical or literature evidence for annular atrophic lichen planus (currently none identified)
- If pursuing the broader lichen planus cluster, drug-specific (not class-effect) evidence for lichen planus pemphigoides, where preliminary class-level literature exists
- Confirmation of South Africa market/registration status before any repurposing pathway is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.